Role of dexmedetomidine in brain injury: a systematic review
Inflammopharmacology · 2025-10 · 33 (10) · 5745-5756
DOI: 10.1007/s10787-025-01946-0 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Inflammopharmacology, online erschienen am 30.09.2025. Verfasst von Rania Zekry und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Damanhour, 22514, Egypt. Hauptthemen laut MEDLINE: Dexmedetomidine, Brain Injuries, Neuroprotective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Damanhour University.
Abstract (Originalsprache)
Background
Brain injuries are major health concern worldwide, that have debilitating effects on patients and affect patients’ quality of life; therefore, we are in urgent need of identifying medications that have neuroprotective properties and help to maintain the patients’ cognitive function. Dexmedetomidine is a sedative medication commonly used in ICU situations; recent studies show that it may have neuroprotective properties via different mechanisms.
Aim
The aim of this article is to review available literature regarding the impact of using dexmedetomidine in various types of brain injury.
Method
A systematic review of the published papers on the PubMed and google scholar that investigated the effects of dexmedetomidine on patients with different brain injuries was employed.
Results
A total of 17 papers were included in this review, of which 1 was a case report, 6 were animal studies, 1 was a retrospective descriptive study, 2 were retrospective cohorts, 5 were randomized controlled trials, 1 was a scoping review, and 1 was a meta-analysis. These papers demonstrated the effects of dexmedetomidine on patients with traumatic brain injury, intracerebral hemorrhage, ischemic brain injury, status epilepticus, and on patients undergoing craniocerebral surgeries.
Conclusion
Dexmedetomidine is a very promising drug to be used in different types of brain injuries and in craniocerebral surgeries because it has demonstrated impressive neuroprotective properties by a variety of mechanisms. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Damanhour, 22514, Egypt.
- Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Damanhour, 22514, Egypt. rehabwrieda@pharm.dmu.edu.eg.
- Department of Critical Care Medicine, Damanhour Medical National Institute, GOTHI, Damanhour, Egypt.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Förderung
- Damanhour University
Zitieren
APA
Zekry, R., Werida, R. H., Hegazy, E. S., & Mostafa, T. M. (2025). Role of dexmedetomidine in brain injury: a systematic review. Inflammopharmacology, 33(10), 5745-5756. https://doi.org/10.1007/s10787-025-01946-0
Vancouver
Zekry R, Werida RH, Hegazy ES, Mostafa TM. Role of dexmedetomidine in brain injury: a systematic review. Inflammopharmacology. 2025;33(10):5745-5756. doi:10.1007/s10787-025-01946-0
BibTeX
@article{Zekry2025,
author = {Zekry, Rania and Werida, Rehab H and Hegazy, Ehab S and Mostafa, Tarek M},
title = {Role of dexmedetomidine in brain injury: a systematic review},
journal = {Inflammopharmacology},
year = {2025},
volume = {33},
number = {10},
pages = {5745--5756},
doi = {10.1007/s10787-025-01946-0}
}
EUVIMED